Edgar Filing: HIRSCH RUSSELL C

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â HIRSCH RUSSELL C

2. Date of Event Requiring Statement (Month/Day/Year)
03/11/2010

3. Issuer Name and Ticker or Trading Symbol
AVEO PHARMACEUTICALS INC [AVEO]

(Last)

(First)

(Middle)

C/O AVEO PHARMACEUTICALS, INC.,Â 75 SIDNEY STREET

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

CAMBRIDGE,Â MAÂ 02139

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	Â ⁽¹⁾	06/16/2019	Common Stock	10,000	$ 8.72	D	Â
Series A Convertible Preferred Stock	03/22/2002	Â ⁽²⁾	Common Stock	10,889	$ ⁽²⁾	I	By Prospect Associates II, L.P. ⁽⁵⁾
Series B Convertible Preferred Stock	07/25/2003	Â ⁽³⁾	Common Stock	10,807	$ ⁽³⁾	I	By Prospect Associates II, L.P. ⁽⁵⁾
Series D Convertible Preferred Stock	03/26/2007	Â ⁽⁴⁾	Common Stock	2,481	$ ⁽⁴⁾	I	By Prospect Associates II, L.P. ⁽⁵⁾
Series A Convertible Preferred Stock	03/22/2002	Â ⁽²⁾	Common Stock	715,037	$ ⁽²⁾	I	By Prospect Venture Partners II, L.P. ⁽⁶⁾
Series B Convertible Preferred Stock	07/25/2003	Â ⁽³⁾	Common Stock	709,714	$ ⁽³⁾	I	By Prospect Venture Partners II, L.P. ⁽⁶⁾
Series D Convertible Preferred Stock	03/26/2007	Â ⁽⁴⁾	Common Stock	162,963	$ ⁽⁴⁾	I	By Prospect Venture Partners II, L.P. ⁽⁶⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
HIRSCH RUSSELL C C/O AVEO PHARMACEUTICALS, INC. 75 SIDNEY STREET CAMBRIDGE,Â MAÂ 02139	Â X	Â	Â	Â

Signatures

/s/ Russell C. Hirsch		03/11/2010
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	This option first became exercisable on July 31, 2009 and vests over a one-year period in equal monthly installments.
(2)	The Series A Convertible Preferred Stock is convertible into Common Stock on a one-for-0.25 basis and has no expiration date.
(3)	The Series B Convertible Preferred Stock is convertible into Common Stock on a one-for-0.25 basis and has no expiration date.
(4)	The Series D Convertible Preferred Stock is convertible into Common Stock on a one-for-0.25 basis and has no expiration date.
(5)	Held by Prospect Associates II, L.P. James B. Tananbaum, M.D., Alexander E. Barkas, Ph.D., David Schnell, M.D. and Russell C. Hirsch, M.D., Ph.D., the managing members of Prospect Management Co. II, LLC, the General Partner of Prospect Associates II, L.P., share voting and investment power over the shares held by Prospect Associates II, L.P., but disclaim beneficial ownership, except to the extent of their pecuniary interest therein.
(6)	Held by Prospect Venture Partners II, L.P. James B. Tananbaum, M.D., Alexander E. Barkas, Ph.D., David Schnell, M.D. and Russell C. Hirsch, M.D., Ph.D., the managing members of Prospect Management Co. II, LLC, the General Partner of Prospect Venture Partners II, L.P., share voting and investment power over the shares held by Prospect Venture Partners II, L.P., but disclaim beneficial ownership, except to the extent of their pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.